Solid biosciences announces $109 million private placement

Charlestown, mass., jan. 08, 2024 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about january 11, 2024, subject to the satisfaction of customary closing conditions. the private placement is being conducted in accordance with applicable nasdaq rules and was priced to satisfy the “minimum price” requirement (as defined in the nasdaq rules).
SLDB Ratings Summary
SLDB Quant Ranking